https://www.selleckchem.com/pr....oducts/sb290157-tfa.
A year after study results were initially reported, the antibody-drug conjugate trastuzumab deruxtecan continues to show strong activity in patients with advanced HER2-positive breast cancer In a phase II trial, the agent elicited a high overall response rate and long median progression-free survival-as well as early, but promising, overall survival results. In Germany, children with life-limiting conditions and complex symptoms are eligible for specialised outpatient palliative care (SOPC). In the federal state of Hesse, SOPC for
Curtir
Comentario
Compartilhar
